Professional Marketing briefs

Share this article:
AxoGen, a peripheral nerve damage devices manufacturer, hired Brad Hedger as VP, sales, a newly created position. Prior to AxoGen, Hedger directed sales and regional management positions at Synthes, before joining Stryker Orthopaedics as director of upper extremity trauma sales. He also founded and led Patient Care, prior to joining AxoGen.

Veeva Systems, a software-as-a-service company specializing in CRM programs, announced the launch of Veeva iRep, a CRM and closed-loop marketing solution built exclusively for the Apple iPad. The iRep program allows sales reps to quickly present e-detail materials, deliver interactive presentations, and show visual data and video content on the iPad, according to a statement on the launch. Marketing firm Intouch Solutions is a partner on the launch, and will provide content for iRep customers.

ReachMD, a CME and healthcare information provider, tapped Arthur Marchesini, Jr. as EVP, sales and business development. Marchesini joins ReachMD from Quintiles Medical Communications, where he was managing director of the US. Marchesini began his career in the pharmaceutical industry, spending over 10 years at Merck in various roles.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?